EGFR and melanoma: As targeted anti-EGFR therapy has shown promising results in decreasing melanoma cell growth and hindering its invasive abilities [46], we examined melanomas and their precursors for mutations that lead to the constitutive activation of kinase activity, such as exon 19 deletions (Del19) [41].